These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25144329)

  • 1. Positron emission tomography in CNS drug discovery and drug monitoring.
    Piel M; Vernaleken I; Rösch F
    J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational PET imaging research.
    Hargreaves RJ; Rabiner EA
    Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomographic imaging in drug discovery.
    Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
    Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
    Burns HD; Van Laere K; Sanabria-Bohórquez S; Hamill TG; Bormans G; Eng WS; Gibson R; Ryan C; Connolly B; Patel S; Krause S; Vanko A; Van Hecken A; Dupont P; De Lepeleire I; Rothenberg P; Stoch SA; Cote J; Hagmann WK; Jewell JP; Lin LS; Liu P; Goulet MT; Gottesdiener K; Wagner JA; de Hoon J; Mortelmans L; Fong TM; Hargreaves RJ
    Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9800-5. PubMed ID: 17535893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging in Central Nervous System Drug Discovery.
    Gunn RN; Rabiner EA
    Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translation of central nervous system occupancy from animal models: application of pharmacokinetic/pharmacodynamic modeling.
    Melhem M
    J Pharmacol Exp Ther; 2013 Oct; 347(1):2-6. PubMed ID: 23857976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of pre-clinical PET imaging for drug development].
    Tsukada H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):231-7. PubMed ID: 22256612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-animal PET: a promising, non-invasive tool in pre-clinical research.
    Schnöckel U; Hermann S; Stegger L; Law M; Kuhlmann M; Schober O; Schäfers K; Schäfers M
    Eur J Pharm Biopharm; 2010 Jan; 74(1):50-4. PubMed ID: 19482080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.
    de Lange EC; Hammarlund-Udenaes M
    Clin Pharmacol Ther; 2015 Apr; 97(4):380-94. PubMed ID: 25670219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography for use in microdosing studies.
    Wagner CC; Müller M; Lappin G; Langer O
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A philosophy for CNS radiotracer design.
    Van de Bittner GC; Ricq EL; Hooker JM
    Acc Chem Res; 2014 Oct; 47(10):3127-34. PubMed ID: 25272291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
    Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
    ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Positron emission tomography: a clinical and biological research tool].
    Kotzki PO
    J Soc Biol; 2004; 198(2):163-8. PubMed ID: 15368968
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Jackson IM; Webb EW; Scott PJH; James ML
    ACS Chem Neurosci; 2022 Jun; 13(12):1675-1683. PubMed ID: 35606334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of PET data in CNS drug discovery and development.
    Varnäs K; Varrone A; Farde L
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards selective CNS PET imaging of the 5-HT
    L'Estrade ET; Erlandsson M; Edgar FG; Ohlsson T; Knudsen GM; Herth MM
    Neuropharmacology; 2020 Aug; 172():107830. PubMed ID: 31669129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can positron emission tomography facilitate paediatric drug development?
    Zimmer L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):595-8. PubMed ID: 19049660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine receptor ligands and PET imaging of the CNS.
    Bauer A; Ishiwata K
    Handb Exp Pharmacol; 2009; (193):617-42. PubMed ID: 19639295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying novel radiotracers for PET imaging of the brain: application of LC-MS/MS to tracer identification.
    Barth V; Need A
    ACS Chem Neurosci; 2014 Dec; 5(12):1148-53. PubMed ID: 24828747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.